Surveillance of the potential drug-drug interactions in the medicine department of a tertiary care hospital

Journal of Clinical and Diagnostic Research

Volumn 6, Issue 7 SUPPL., 2012, Pages 1258-1261

  Soherwardi, Shahabudin ^a   Chogtu, Bharti ^a   Faizal, P ^b  

^a KASTURBA MEDICAL COLLEGE   (India)

^b Department of Pharmacology Kasturba Medical College Manipal University ^*  (India)

Author keywords

Drug drug interactions; Mild; Moderate and severe interactions

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CIPROFLOXACIN; CLOPIDOGREL; COTRIMOXAZOLE; DIGOXIN; FUROSEMIDE; GENTAMICIN; INSULIN; IRON; LAMIVUDINE; NICOTINIC ACID; PANTOPRAZOLE; PENICILLIN DERIVATIVE; RAMIPRIL; SPIRONOLACTONE; TERBUTALINE; THEOPHYLLINE; ZINC;

ADULT; AGED; ARTICLE; BLEEDING; CHILD; DIABETES MELLITUS; DIGITALIS INTOXICATION; DRUG BIOAVAILABILITY; DRUG SURVEILLANCE PROGRAM; FEMALE; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; HYPERKALEMIA; HYPERTENSION; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; PROSPECTIVE STUDY; SIDE EFFECT; STOMACH PH; TERTIARY CARE CENTER;

EID: 84902170604     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Costa AJ. Potential drug interactions in an ambulatory geriatric population. Fam Pract. 1991;8:234-36.
2. Mahmood M, Malone DC, Skrepnek GH, Abarka J, Armstrong EP, Murphy JE, et al. Potential drug drug interactions within the veteran affairs medical centers. Am J Health-Syst Pharm 2007;64: 1500-05.
3. Micromedex® Healthcare Series. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc., 2007. Available from URL: https://www.thomsonhc.com/hcs/librarian/ [Accessed 2011 Jul 5].
4. Almeida SM, Gama CS, Akamine N. The prevalence and the classification of drug drug interactions in intensive care patients. Einstein 2007;5(4):347-51.
5. Doucet J, Chassagne P, Trivalle C, Landrin I, Pauty MD, Kadri N, et al. Drug-Drug interactions which are related to hospital admissions in older adults: a prospective study on 1000 patients. J Am Geriatr Soc. 944-48.
6. Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging. 1998;12:485-94.
7. Johnson JA, Bootman JL. Drug related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995: 155:1949-56.
8. Mallet L, Spinewine A, Huang A. The challenge of managing the drug interactions in elderly people. Lancet 2007;370: 185-91.
9. White JR, Campbell RK. Dangerous and common drug interactions in patients with diabetes mellitus. Endocrinology and Metabolism Clinics 2000; 29:789-801
10. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. The effect of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
11. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. The aspirin and clopidogrel combination which was compared with clopidogrel alone after a recent ischemic stroke or a transient ischemic attack in high risk patients (MATCH): a randomized, double blind, placebo controlled trial. Lancet 2004;364: 331-37.
12. Brunton LL, Chabner BA, Knollman BC, Eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 12th ed., McGraw Hill, New York, USA, 2011;1312.
13. Ghaly H, Kriet C, Sahin S, Pfloger A, Holzgrabe U, Zunkler BJ, et al. The insulinotropic effects of the fluoroquinolones. Biochemical Pharmacology 2009; 77: 1040-52.
14. Gajjar DA, LaCretab FP, Kollia GD, Stolz RR, Berger S, Smith WB, et al. The effect of multidose gatifloxacin or ciprofloxacin in patients with non-insulin dependent diabetes mellitus which was maintained with diet and exercise. Pharmacotherapy 2000; 20: 76S-86S.
15. Pitt B, Zannad F, Remme WJ, Cody R, Castargne A, Perez A.The effect of spironolactone on the morbidity and the mortality in patients with severe heart failure. N Eng J Med 1999; 341: 709-17.
16. Fenester PE, Hager WD, Goodman MM. The Digoxin-quinidine-spironolactone interaction. Clin Pharmacol Ther 1984; 36: 70-73.
17. Johnston RT, De Bono DP, Nyman CR. Preventable sudden death in patients who received angiotensin converting enzyme inhibitors and loop/potassium sparing diuretic combinations. Int J Cardiol 1992;34:213-15.
18. Wregner E, Muller R, Moesenthin M, Welte T, Frolich JC, Neumann KH. Interaction of spironolactone with the ACE inhibitors or an angiotensin receptor blocker: an analysis of 44 cases. BMJ 2003; 327: 147-49.
19. Schepkens H, Vanholder R, Billiouw JM, Lamiere N. Life-threatening hyperkalemia during a combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. The American Journal of Medicine 2001; 110: 438-41.
20. Gagne JJ, Maio V, Rabinowitz C. The prevalence and the predictors of the potential drug- drug interactions in Regione Emilia-Romagna, Italy. J Clin Pharm Ther. 2008; 33: 141-51.
21. Magro L, Conforti A, Del Zotti F, Leone R, Iorio ML, Meneghelli I, et al. Identification of the severe potential DDIs by using an Italian general-practitioner database. Eur J Clin Pharmacol 2008; 64: 303-09.